Evolva appoints Oliver Walker as CFO

Strong track record as CFO of Nobel Biocare, Sonova and Stratec

29. Nov 2016

29 November 2016 – Evolva (SIX: EVE) Evolva announces the appointment of Oliver Walker as its Chief Financial Officer (CFO) effective 1st December 2016.

Oliver Walker is a finance executive with more than 20 years of experience in international companies, both listed and privately-held, and was active in high growth industries and mature industries alike. Amongst other senior positions he was previously CFO of several leading Life Sciences companies, including Sivantos (Singapore), Nobel Biocare, Sonova and Stratec (all Switzerland). His experience covers all aspects of finance including M&A, capital market transactions, treasury, reporting and fundraising. Oliver has an MSc in Business Administration & Economics at the University of Berne. He is a Swiss national, born in 1969.

Neil Goldsmith, CEO of Evolva said, “I look forward to working with Oliver to take Evolva to the next stage. His experience as an entrepreneurial CFO in diverse life science, high tech and manufacturing companies will be very useful to Evolva. Oliver has a strong track record in driving operations and managing growth and brings an extensive network, both in the Swiss financial sector and abroad.”

Oliver said, “I am excited to join Evolva and make a contribution to bringing this dynamic and innovative company to strong and sustainable profitability. Jakob has given the company a solid financial foundation and I am confident my experience will be valuable in building on this basis.”

The current CFO, Jakob Dynnes Hansen, will remain at Evolva on a part-time basis to secure a smooth transition and is expected to depart in the second quarter of 2017. Jakob will return to his native Denmark, taking up a part time CFO position at Acesion Pharma, a young pharma-biotech company.

– ends –

Download Press Release in English

Download Press Release in German

About Evolva

Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information see www.evolva.com. Questions about our approach? Have a look at our video.

 

Contact Details
Evolva

Neil Goldsmith
CEO
[email protected]
+ 41 61 485 2005
Jakob Dynnes Hansen
CFO
[email protected]
+ 41 61 485 2034
Paul Verbraeken
IR
[email protected]
+ 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

cancel

Sign up to receive our
Press Releases!

Sign up